Comparable stake leader
Christopher Bunka
SEC ownership of Lexaria Bioscience Corp.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001348362.
Disclosed value leader
Christopher Bunka
Comparable rows
0/39
Latest evidence
31 Mar 2026
- Public ticker
- LEXX on Nasdaq
- Parsed ownership sources
-
3/4/5 and 13F
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Christopher Bunka
Ranking: Comparable ownership first, then disclosed value
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001348362
- Issuer location
- Kelowna, British Columbia, Canada
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
1 signal
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Lexaria Bioscience Corp. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Christopher Bunka
Disclosed value leader
Christopher Bunka
Comparable rows
0/39
Latest evidence
31 Mar 2026
3/4/5
13F
Highest disclosed value: $533,006
39 rows are not safely comparable across share classes.
Showing 1-8 of 39 holder rows.
Quick read
Christopher Bunka has the largest disclosed position value at $533K.
0 of 39 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Christopher Bunka's linked filing trail.
Disclosed position value
Top 5
Christopher Bunka
$533K
Richard Christopher
$363.6K
Invenomic Capital Management LP
$345K
John Martin Docherty
$322.5K
GEODE CAPITAL MANAGEMENT, LLC
$229.5K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-8 of 39 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Christopher Bunka |
3/4/5
Director
|
—
mixed-class rows
|
$533,006
740,289 shares
mixed-class rows
|
+$25,241 | 17 Mar 2026 |
| Richard Christopher |
3/4/5
Chief Executive Officer, Director
|
—
mixed-class rows
|
$363,611
415,000 shares
mixed-class rows
|
+$13,641 | 29 Jul 2025 |
| Invenomic Capital Management LP |
13F
Company
|
—
class O/S missing
|
$344,995
442,301 shares
|
— | 31 Mar 2026 |
| John Martin Docherty |
3/4/5
President & CSO, Director
|
—
mixed-class rows
|
$322,458
370,285 shares
mixed-class rows
|
+$4,989 | 29 Jul 2025 |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
Company
|
—
class O/S missing
|
$229,471
294,157 shares
|
— | 31 Mar 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC |
13F
Company
|
—
class O/S missing
|
$173,389
222,293 shares
|
— | 31 Mar 2026 |
| Michael Elliot Shankman |
3/4/5
Chief Financial Officer
|
—
class O/S missing
|
$122,000
100,000 shares
|
— | 15 May 2025 |
| TORONTO DOMINION BANK |
13F
Company
|
—
class O/S missing
|
$109,279
140,013 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$49,085.
Buys
$49,085
Insiders: 5
Sells
$0
Insiders: 0
Net
+$49,085
Shares: +53,626
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 53,626
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 53,626 | 0 | $49,085 | $0 | +$49,085 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-12 of 12 reporting-owner rows connected to Lexaria Bioscience Corp.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
12
Largest Forms 3/4/5 holder
Christopher Bunka
Net 12M change
+$49,086
Latest report
17 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Christopher Bunka | Director | $533,006 | +$25,241 | +5% | Mixed | 17 Mar 2026 |
| Richard Christopher | Chief Executive Officer, Director | $363,611 | +$13,641 | +3.9% | Mixed | 29 Jul 2025 |
| John Martin Docherty | President & CSO, Director | $322,458 | +$4,989 | +1.6% | Mixed | 29 Jul 2025 |
| Michael Elliot Shankman | Chief Financial Officer | $122,000 | Mixed | 15 May 2025 | ||
| Nicholas W. Baxter | Director | $90,280 | Mixed | 15 May 2025 | ||
| William Edward McKechnie | Director | $71,296 | +$4,532 | +6.8% | Mixed | 29 Jul 2025 |
| Vanessa Carle | Secretary | $65,932 | +$683 | +1% | Mixed | 29 Jul 2025 |
| Albert L. Reese Jr. | Director | $65,778 | Mixed | 15 May 2025 | ||
| Baljinder Bhullar | Director | $15,860 | Mixed | 15 May 2025 | ||
| Catherine C. Turkel | Director | $9,703 | Filing P/S | 12 Aug 2024 | ||
| Gregory Downey | Chief Financial Officer | $4,084 | Filing P/S | 14 Oct 2022 | ||
| Nelson Cabatuan | Chief Financial Officer | Mixed | 14 Mar 2024 |
Recent insider transactions for Lexaria Bioscience Corp.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Christopher Bunka | LEXX | common shares | Gift | -26.8% | -100,000 | 273,543 | 17 Mar 2026 | Direct | ||
| Christopher Bunka | LEXX | common shares | Purchase | 4.41% | $10,866 | $0.9131 | 11,900 | 281,912 | 30 Jul 2025 | Private Holding Company |
| Christopher Bunka | LEXX | common shares | Purchase | 6.13% | $14,375 | $0.9215 | 15,600 | 270,012 | 29 Jul 2025 | Private Holding Company |
| William Edward McKechnie | LEXX | common shares | Purchase | 37.9% | $4,532 | $0.9063 | 5,000 | 18,191 | 29 Jul 2025 | Direct |
| John Martin Docherty | LEXX | common shares | Purchase | $4,989 | $0.9280 | 5,376 | 5,376 | 29 Jul 2025 | Direct | |
| Vanessa Carle | LEXX | common shares | Purchase | $682 | $0.9100 | 750 | 750 | 29 Jul 2025 | Direct | |
| Richard Christopher | LEXX | common shares | Purchase | 30% | $13,641 | $0.9094 | 15,000 | 65,000 | 29 Jul 2025 | Direct |
* marks a reported price that did not pass the local price check.